论文部分内容阅读
目的:探讨2型糖尿病治疗中DPP-4抑制剂的疗效作用。方法:随机选取2013年3月至2015年11月来该院就诊的60例2型糖尿病患者进行研究,将其随机分为治疗组与对照组各30例,治疗组给予DPP-4抑制剂沙格列汀治疗,对照组给予阿卡波糖治疗,对比治疗后患者的Hb A1c、空腹与餐后血糖变化。结果:治疗组的Hb A1c、空腹与餐后血糖和对照组相比明显下降(P<0.05)。结论:对2型糖尿病患者采用DPP-4抑制剂治疗,可以有效改善患者的Hb A1c、空腹与餐后血糖,具有安全性高、副作用小、效果显著、可耐受性等特点,值得推广使用。
Objective: To investigate the curative effect of DPP-4 inhibitor in the treatment of type 2 diabetes mellitus. Methods: A total of 60 patients with type 2 diabetes who were treated in our hospital from March 2013 to November 2015 were randomly divided into treatment group and control group, 30 cases each. The treatment group was given DPP-4 inhibitor sand The control group was given acarbose treatment, and the Hb A1c, fasting and postprandial blood glucose in the patients after treatment were compared. Results: Hb A1c, fasting and postprandial blood glucose in the treatment group were significantly lower than those in the control group (P <0.05). Conclusion: DPP-4 inhibitor can improve Hb A1c, fasting and postprandial blood glucose in patients with type 2 diabetes mellitus with high safety, little side effects, remarkable effect and tolerability. It is worth using .